Pharmaceuticals

Camzyos Demonstrates Efficacy and Safety in Treating Symptomatic Obstructive Hypertrophic Cardiomyopathy

bexib
By bexib 0 Min Read

Results from the Phase III EXPLORER-LTE trial found that Camzyos maintained efficacy in treating symptomatic obstructive hypertrophic cardiomyopathy after 3.5 years of treatment.

You Might Also Like

FDA approves AstraZeneca’s Imfinzi for mismatch repair deficient primary advanced or recurrent endometrial cancer

Pharma Pulse 8/16/24: DCTS: Bankruptcy or Breakthrough? U.S. Drug Pricing Initiative Saves Over $7.5 Billion

A big bet, a bold step

FDA approves Servier’s Voranigo for grade 2 IDH-mutated glioma

Pharma Pulse 7/22/24: JD Vance’s AI Agenda, Fighting the Flu with Supplements and More

Share This Article
Previous Article Who will be tomorrow’s world’s richest people? We interviewed teenagers attending the world’s most expensive schools to find out
Next Article Internal and External Page Linking Tips
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Progress of metal cutting technology: Innovative innovation, sustainability, and future labor
Manufacturing
Ceratizit showcases innovation, sustainability and cutting-edge solutions at IMTEX 2025
Manufacturing
Goldman launches an internal GEN AI Assistant with 10K employees
Banking
Taiwan emerges as key player in Indian machine tools market with 20.8% growth
Manufacturing